Nanoplasmonic biosensing platform

为快速、实时识别生物标志物而设计的生物传感设备，如今在许多医疗保健、医疗和制药应用中都是必不可少的。此外，这些领域的现代应用不断要求下一代生物传感器小型化、自动化和多路复用（即能够同时量化几种感兴趣的物种）。事实上，下一代生物传感设备的发展能够解决这样的需求提出了一个重要的多学科挑战等待解决。需要这种下一代生物传感装置的一个重要健康问题是源于心力衰竭（HF）的疾病，这是一个影响全世界数百万人的全球公共卫生问题。该项目旨在开发用于HF生物标志物检测的多路纳米等离子体生物传感平台的原理验证演示。等离子体生物传感器是一类光学生物传感器件，具有实时响应快、灵敏度高、芯片级集成等特点。我们将研究一种能够复用几十个通道的传感架构，以便进行自动化和准确的免疫分析测量，这种测量有可能超过用于检测HF生物标志物的传统临床技术（例如ELISA）。所请求的Catalyst赠款将使Berini教授（渥太华大学）和De Leon教授（蒙特雷理工大学）的小组之间能够开展协同的跨学科研究合作。研究人员的专业知识结合起来，将开辟一条新的研究途径，提供涉及先进生物传感技术的解决方案，应用于医学诊断和医学研究的重要需求，如检测与HF相关的生物标志物。

Biosensing devices designed for fast, real-time identification of biomarkers are nowadays essential for many healthcare, medical and pharmaceutical applications. In addition, modern applications in these fields constantly demand for the next generation of biosensors to be miniaturized, automated, and multiplexed (i.e, capable to quantify several species of interest at the same time). Indeed, the development of next-generation biosensing devices capable of tackling such demands poses an important multidisciplinary challenge waiting to be addressed. An important health problem that demands such a next-generation biosensing device is that which originates from heart failure (HF) conditions, a global public health problem affecting millions of people across the world. This project aims at developing a proof-of-principle demonstration of a multiplexed nanoplasmonic biosensing platform for HF biomarker detection. Plasmonic biosensors, a class of optical biosensing devices, feature characteristics such as a fast real-time response, high sensitivity, and chip-scale integration. We will investigate a sensing architecture which is capable of multiplexing several tens of channels in order to carry out automated and accurate immunoassay measurements that hold the potential to outperform conventional clinical-based techniques (e.g. ELISA) used in the detection of HF biomarkers. The requested Catalyst grant will enable a synergetic interdisciplinary research collaboration to be initiated between the groups of Prof. Berini (uOttawa) and Prof. De Leon (Tec de Monterrey). The researchers' combined expertise will enable a new research avenue offering solutions that involve advanced biosensing technologies applied to important needs in medical diagnosis and medical research, such as the detection of biomarkers related to HF.